Bridges Investment Management Inc. lifted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 6.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 192,031 shares of the company's stock after purchasing an additional 12,165 shares during the quarter. Bridges Investment Management Inc.'s holdings in AbbVie were worth $40,234,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of ABBV. Abound Financial LLC purchased a new stake in AbbVie in the first quarter valued at approximately $30,000. EnRich Financial Partners LLC increased its stake in AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after buying an additional 110 shares during the period. Prudent Man Investment Management Inc. acquired a new stake in AbbVie during the 4th quarter valued at approximately $32,000. Pinney & Scofield Inc. acquired a new stake in AbbVie in the fourth quarter valued at $36,000. Finally, Inlight Wealth Management LLC acquired a new position in AbbVie in the first quarter worth about $42,000. Institutional investors and hedge funds own 70.23% of the company's stock.
Analyst Upgrades and Downgrades
ABBV has been the topic of several analyst reports. Wall Street Zen lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Erste Group Bank raised AbbVie to a "strong-buy" rating in a research report on Monday, March 17th. Cantor Fitzgerald initiated coverage on AbbVie in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price objective for the company. Guggenheim raised their price objective on shares of AbbVie from $214.00 to $216.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Finally, Evercore ISI lifted their target price on shares of AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $211.29.
View Our Latest Stock Report on AbbVie
AbbVie Stock Up 0.5%
ABBV stock traded up $0.97 during trading on Wednesday, hitting $190.74. 5,593,883 shares of the company's stock were exchanged, compared to its average volume of 6,289,094. The stock has a market capitalization of $336.92 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 1.28 and a beta of 0.48. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $218.66. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The business has a 50-day moving average price of $187.19 and a two-hundred day moving average price of $188.77.
AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The company had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same quarter last year, the company posted $2.31 earnings per share. The business's quarterly revenue was up 8.4% compared to the same quarter last year. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.
AbbVie Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.44%. AbbVie's payout ratio is 279.15%.
AbbVie Company Profile
(
Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
See Also

Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.